Enzyme:CYP2B6: Difference between revisions
From Pharmacopedia
More actions
| [checked revision] | [checked revision] |
MDElliottMD (talk | contribs) m MDElliottMD moved page Pharmacopedia:Pharmacogenomics sandbox/Enzyme CYP2B6 to Enzyme:CYP2B6: Migrate enzyme entity pages from Pharmacogenomics sandbox to the new Enzyme: namespace |
MDElliottMD (talk | contribs) Add scope="col" to the data-table column headers for screen-reader association (ADA audit M5; designer-claude 2026-05-22) |
||
| Line 13: | Line 13: | ||
{| class="wikitable sortable mw-collapsible mw-collapsed" style="width:100%;" | {| class="wikitable sortable mw-collapsible mw-collapsed" style="width:100%;" | ||
|+ style="white-space:nowrap; text-align:left;" | near-complete CYP2B6 substrate table (click to expand) | |+ style="white-space:nowrap; text-align:left;" | near-complete CYP2B6 substrate table (click to expand) | ||
! Substrate !! Therapeutic class !! CYP2B6 contribution !! Clinical notes | ! scope="col" | Substrate !! scope="col" | Therapeutic class !! scope="col" | CYP2B6 contribution !! scope="col" | Clinical notes | ||
|- | |- | ||
| [[Artemether]] || Antimalarial || major || CYP2B6 is a principal route; relevant to the large-scale use of artemisinin-combination therapy in malaria-endemic regions. | | [[Artemether]] || Antimalarial || major || CYP2B6 is a principal route; relevant to the large-scale use of artemisinin-combination therapy in malaria-endemic regions. | ||